Skip to Content

Trodelvy (sacituzumab govitecan) – A new effective treatment option for breast cancer

Data presented at SABCS22 shows that Trodelvy, sacituzumab govitecan, is an effective new treatment option for patients with pre-treated, endocrine-resistant HR+/HER2- metastatic breast cancer.

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top